|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2003-6-17
|
|
pubmed:abstractText |
Gemfibrozil increases the plasma concentrations of active acid forms of cerivastatin, lovastatin, and simvastatin. Pravastatin pharmacokinetics differs from those of these 3 statins, which are extensively metabolized. Our aim was to study the effects of gemfibrozil on the pharmacokinetics of pravastatin.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
538-44
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12811363-Adult,
pubmed-meshheading:12811363-Area Under Curve,
pubmed-meshheading:12811363-Biological Availability,
pubmed-meshheading:12811363-Cross-Over Studies,
pubmed-meshheading:12811363-Drug Interactions,
pubmed-meshheading:12811363-Female,
pubmed-meshheading:12811363-Gemfibrozil,
pubmed-meshheading:12811363-Half-Life,
pubmed-meshheading:12811363-Humans,
pubmed-meshheading:12811363-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:12811363-Hypolipidemic Agents,
pubmed-meshheading:12811363-Kidney,
pubmed-meshheading:12811363-Male,
pubmed-meshheading:12811363-Pravastatin
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.
|
|
pubmed:affiliation |
Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
